Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo in generalized anxiety disorder

被引：0

作者：

Stein, D. ^{[1
,2
]}

Ahokas, A. ^{[3
]}

Jarema, M. ^{[4
]}

Avedisova, A. S. ^{[5
]}

Vavrusova, L. ^{[6
]}

Chaban, O. ^{[7
]}

Olivier, V. ^{[8
]}

Gruget, C. ^{[8
]}

Picarel-Blanchot, F. ^{[8
]}

De Bodinat, C. ^{[8
]}

机构：

[1] Univ Cape Town, Cape Town, South Africa

[2] Mt Sinai Sch Med, Dept Psychiat, Cape Town, South Africa

[3] Mehilainen Clin, Dept Psychiat, Helsinki, Finland

[4] Ctr Terapii Dialog, Warsaw, Poland

[5] Psychiat Hosp 12, Moscow, Russia

[6] Univ Hosp Bratislava, Dept Psychiat, Bratislava, Slovakia

[7] Railway Clin Hosp, Psychoneurol Dept, Kiev, Ukraine

[8] Inst Rech Int Servier, Pole Innovat Therapeut Neuropsychiat, Suresnes, France

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷

关键词：

D O I：

10.1016/S0924-977X(16)31678-9

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P.4.b.003

引用

页码：S601 / S602

页数：2

共 50 条

[21] Efficacy and Safety of 24 Weeks of Therapy with Bendroflumethiazide 1.25 mg/day or 2.5 mg/day and Potassium Chloride Compared with Enalapril 10 mg/day and Amlodipine 5 mg/day in Patients with Mild to Moderate Primary HypertensionA Multicentre, Randomised, Open Study [J].

S. Rasmussen ;

N. Borrild ;

J. Vang Andersen .

Clinical Drug Investigation, 2006, 26 :91-101

[22] Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with Enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension - A multicentre, randomised, open study [J].

Rasmussen, S ;

Borrild, N ;

Andersen, FV .

CLINICAL DRUG INVESTIGATION, 2006, 26 (02) :91-101

[23] Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50 mg/day) and escitalopram (10-20 mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study [J].

Udristoiu, T. ;

Dehelean, P. ;

Nuss, Ph ;

Raba, V. ;

Picarel-Blanchot, F. ;

de Bodinat, C. .

JOURNAL OF AFFECTIVE DISORDERS, 2016, 199 :6-12

[24] EVALUATION OF EFFICACY AND SAFETY OF KETOPROFEN (200 MG/DAY) COMPARED TO DICLOFENAC (150 MG/DAY) IN THE TREATMENT OF ACUTE LOMBOCIATALGIA [J].

RACHID, A .

REVISTA BRASILEIRA DE MEDICINA, 1992, 49 (1-2) :37-40

[25] Efficacy and safety of agomelatine (25 mg/50 mg), a melatonergic and specific serotonergic antidepressant, in the treatment of major depressive disorder: A randomised, double-blind placebo-controlled study [J].

Emsley, R .

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 :S350-S351

[26] Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients [J].

Stein, EA ;

Davidson, MH ;

Dobs, AS ;

Schrott, H ;

Dujovne, CA ;

Bays, H ;

Weiss, SR ;

Melino, MR ;

Stepanavage, ME ;

Mitchel, YB .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (03) :311-316

[27] Efficacy and safety of duloxetine 120 mg/day in the treatment of depression [J].

Goldstein, DJ ;

Mallinckrodt, C ;

Lu, Y ;

Detke, M ;

Demitrack, MA .

JOURNAL OF AFFECTIVE DISORDERS, 2002, 68 (01) :108-108

[28] Efficacy and Safety of Milnacipran 100 mg/day in Patients With Fibromyalgia [J].

Arnold, Lesley M. ;

Gendreau, R. Michael ;

Palmer, Robert H. ;

Gendreau, Judy F. ;

Wang, Yong .

ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2745-2756

[29] Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial [J].

Loebel, Antony ;

Cucchiaro, Josephine ;

Sarma, Kaushik ;

Xu, Lei ;

Hsu, Chuanchieh ;

Kalali, Amir H. ;

Pikalov, Andrei ;

Potkin, Steven G. .

SCHIZOPHRENIA RESEARCH, 2013, 145 (1-3) :101-109

[30] Multicentre, randomized, placebo controlled study to evaluate the efficacy, safety and tolerability of two doses of oral laquinimod (0.6mg/day and 1.2mg/day) for the treatment of patients with relapsing remitting multiple sclerosis [J].

Vollmer, T. ;

Montalban, X. ;

Comi, G. ;

Ziemssen, T. ;

Boyko, A. ;

Vermersch, P. ;

Sasson, N. ;

Gorfine, T. ;

Knappertz, V. ;

Filippi, M. .

MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) :488-489

← 1 2 3 4 5 →